Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ906MR)

This product GTTS-WQ906MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ906MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4133MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ13226MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ1473MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ4901MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ9253MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ6932MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ13315MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ636MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 8c10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW